Industry news that matters to you.  Learn more

QIAGEN Launches Streamlined Bioinformatics for RNA Sequencing of Liquid Biopsies

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced introduction of its unique RNA-seq Explorer Solution, a bioinformatics-driven approach to analysis and interpretation of “omics” data from liquid biopsy-based research. RNA-seq Explorer Solution is a new tool which integrates Ingenuity® Pathway Analysis™, Biomedical Genomics Workbench® and other QIAGEN bioinformatics solutions to generate clear insights for research into improved detection, diagnosis and treatment of cancer. The solution will be demonstrated at the American Association for Cancer Research (AACR) Annual Meeting in New Orleans.

QIAGEN Partners to Develop Novel Companion Diagnostic in Lung Cancer

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) recently announced a partnership with Mirati Therapeutics, Inc. (NASDAQ: MRTX) to co-develop and commercialize a companion diagnostic test to guide the use of Mirati’s glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer (NSCLC). The companies aim to create a regulator-approved test to personalize treatment decisions in NSCLC by detecting RNA biomarkers produced by exon 14 skipping mutations of the MET gene.

QIAGEN Partners with IT leaders on Novel Infrastructure for Genomics

QIAGEN N.V. recently announced it will demonstrate the result of its work with information technology leaders Intel and BioTeam at Bio-IT World. Together these collaborations create infrastructure solutions that make population-scale genomic analysis feasible for more researchers. QIAGEN Bioinformatics has worked with Intel to develop a computational solution and reference architecture for whole genome analysis, and with BioTeam to create a proof-of-concept high-performance computing (HPC) appliance. QIAGEN is demonstrating both of these solutions at the Bio-IT World Conference and Expo from April 5-7 in Boston.

QIAGEN Expands Clinical Decision Support for NGS in Oncology Labs

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced enhancements to its QIAGEN Clinical Insight® (QCI™) clinical decision support solution, which streamlines the annotation, interpretation and reporting of next-generation sequencing results (NGS) for clinical laboratories.

DNAnexus Partners With QIAGEN to Integrate Its Cloud Genomics Platform With Ingenuity Variant Analysis

DNAnexus Inc., the leader in cloud-based genome informatics and data management, today announced that QIAGEN, a leading global provider of Sample to Insight solutions to transform biological materials into valuable molecular insights, has integrated the DNAnexus cloud genomics platform with Ingenuity Variant Analysis, QIAGEN’s leading variant interpretation solution. Researchers globally now have the ability to choose a sequencer independent, cloud-based solution for analyzing and interpreting their NGS data by uploading raw sequencing data into the scalable DNAnexus cloud platform and seamlessly generating uniquely actionable biological insights through QIAGEN’s Ingenuity Variant Analysis.